Gracell Biotechnologies
Company Type: Therapeutic development
Main focus: Advancing autologous and allogeneic CAR-T cell therapies to treat various cancers and autoimmune diseases
Company stage: Clinical
Diseases: Haematological and solid cancers, Systemic Lupus Erythematosus
Genome-editing tool: CRISPR-Cas9
Funding stage: Post-IPO Equity
Location: Suzhou, Jiangsu, China
Website: www.gracellbio.com
Pipeline: www.gracellbio.com/pipeline/
Partners:
Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich pipeline of autologous and allogeneic product candidates designed to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality and a lack of effective CAR-T therapies for solid tumours and autoimmune diseases.